카사바 사이언스(SAVA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.72 (+5.23%), 시가총액 $0.11B, 52주 최저~최고 $1.21 ~ $4.64.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
카사바 사이언스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
카사바 사이언스의 현재 주가는 $0.72 (+5.23%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
카사바 사이언스의 시가총액은 약 $0.11B입니다.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is c